Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jul
24
2023
Regulators Send Warning Letter to Hospitals and Telehealth Providers About Tracking Technology Use Sheppard, Mullin, Richter & Hampton LLP
Mar
5
2020
Nota Bene Episode 71: Shifting Regulatory Landscapes at the FDA: Cannabis, Vaping and Intelligent Medical Devices with Allison Fulton [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Mar
10
2020
Prop 65 Warnings and Acrylamide in Food – Can I Still Have My Coffee and Drink it Too? Sheppard, Mullin, Richter & Hampton LLP
Mar
16
2020
FDA Grants COVID-19 Diagnostic Emergency Use Authorizations, And Other Recent FDA Actions With to Address COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Apr
1
2020
Gifting Goods & Services to the U.S. Government in the Wake of the Coronavirus Outbreak Sheppard, Mullin, Richter & Hampton LLP
Oct
18
2023
FDA’s Proposed Rule on LDT Regulation and the Debate over Agency Deference Sheppard, Mullin, Richter & Hampton LLP
Jul
17
2020
Clearing the Air: FinCEN Guidance May Help Banks Find Their Way in the Field of Hemp Financing Sheppard, Mullin, Richter & Hampton LLP
Apr
11
2024
China Semiconductor Export Regulations, Episode V – Updates and Corrections to the Advanced Computing and Semiconductor Regulations Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2021
FDA’s Action Plan for Artificial Intelligence: Highlights and Insights for Developers Sheppard, Mullin, Richter & Hampton LLP
Mar
8
2021
California Legislative Update: Employment-Related Bills on the Horizon Sheppard, Mullin, Richter & Hampton LLP
Nov
16
2010
Proposition 23's Failure Means Full Speed Ahead on AB 32 Sheppard, Mullin, Richter & Hampton LLP
Feb
9
2018
Temporal Proximity Is Not Enough: Third Circuit Nixes FCA/Anti-Kickback Suit For Failure To Link Alleged Scheme to Claims Sheppard, Mullin, Richter & Hampton LLP
Jul
30
2013
Food and Drug Administration (“FDA”) Draft Guidance For Industry On Pre-Launch Activities Importation Requests: Dead On Arrival? Sheppard, Mullin, Richter & Hampton LLP
Aug
9
2013
Unusual Circumstances: California Supreme Court Upholds Limited Use of Future Conditions Baseline Under California Environmental Quality Act (CEQA) Sheppard, Mullin, Richter & Hampton LLP
Dec
30
2021
San Francisco Passes Measure Requiring Sick Leave for Domestic Workers – “First of Its Kind” Sheppard, Mullin, Richter & Hampton LLP
Feb
14
2019
HIMMS19 Conference – Blockchain Symposium Recap Sheppard, Mullin, Richter & Hampton LLP
May
17
2022
California Cannabis Farmers May Finally Get Some Relief Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2019
OH SNAP! Supreme Court to Take on Meaning of Key FOIA Exemption Sheppard, Mullin, Richter & Hampton LLP
Jul
26
2022
New Litigation Continues to Challenge the Social Equity and Scoring Process of the Illinois Cannabis Regulation And Tax Act Sheppard, Mullin, Richter & Hampton LLP
Nov
11
2014
Amgen/Sandoz Disputes Will Clarify BPCIA (Biologics Price Competition and Innovation Act) Issues Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2014
Dole Defeats “All Natural Claims” for Sweet Victory Sheppard, Mullin, Richter & Hampton LLP
Nov
28
2022
Federal Judge in NY Issues Preliminary Injunction to Block Retail Cannabis Licenses on Constitutional Grounds Sheppard, Mullin, Richter & Hampton LLP
Mar
21
2023
California’s Toxic-Free Cosmetics Act Bans 24 Ingredients From Cosmetic Products Sheppard, Mullin, Richter & Hampton LLP
Apr
11
2023
New California Bill Seeks to Eliminate Certain Food Additives Sheppard, Mullin, Richter & Hampton LLP
Aug
25
2023
FDA’s Office of Prescription Drug Promotion Issues Second Untitled Letter of the Year to Exeltis for Misleading Statements Relating to SLYND® Sheppard, Mullin, Richter & Hampton LLP
Mar
30
2020
Key Health Care Provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) Sheppard, Mullin, Richter & Hampton LLP
Apr
9
2020
Update: Key FDA Actions for COVID-19 Devices and Therapies Sheppard, Mullin, Richter & Hampton LLP
Oct
30
2023
High Protections on Information Relating to Employees’ Cannabis Use Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins